HIV-1 infection kinetics, drug resistance, and long-term safety of pre-exposure prophylaxis with emtricitabine plus tenofovir alafenamide (DISCOVER): week 144 open-label extension of a randomised, controlled, phase 3 trial

作者：David A. Wohl, Christoph D. Spinner, Jason Flamm, C. Bradley Hare, Susanne Doblecki‐Lewis, Peter Ruane, Jean‐Michel Molina, Anthony Mills, Cynthia Brinson, Moti Ramgopal, Amanda Clarke, Gordon Crofoot, Claudia Martorell, Christoph C Carter, Stephanie Cox, J. Carlo Hojilla, Yongwu Shao, Moupali Das, Alexander Kintu, Jared M. Baeten, Robert M. Grant, Karam Mounzer, Kenneth H. Mayer · 发表于：The Lancet HIV · 年份：2024 · DOI：10.1016/s2352-3018(24)00130-9 · 被引用次数：6 · 研究领域：HIV/AIDS drug development and treatment、HIV/AIDS Research and Interventions、HIV Research and Treatment